Ann: Trading Halt, page-39

With respect to low market caps and undervalued opportunities in the Biotech space - I feel like it's also worth reminding myself and others just how devastating 2022 & 2023 was for small-cap biotech. So many of them got viciously sold down for two years regardless of fundamentals. After everything went parabolic in late 2021 it's been a blood bath. This is certainly the case for the five biotechs I hold. They've had to raise capital at terrible prices and there's been little to no interest. This is why, in my view small-cap biotech has been an excellent contrarian trade since late 2023 and the beginning of this year. Things are beginning to wake up again now